



**Media Release**

**6 December 2007**

**ANU CONNECT VENTURES INVESTS IN NEW RADIATION STORAGE PHOSPHOR**

A materials science company spun out of the University of New South Wales' ADFA campus, has received a \$1.0 million investment from a syndicate including ANU Connect Ventures and Australian Capital Ventures to develop an innovative new radiation storage phosphor.

The phosphor captures x-rays and enables x-ray dosage to be measured, presenting a new opportunity for monitoring exposure to radiation for health care professionals and a new avenue for imaging materials such as chest x-rays and mammography. The technology also has potential applications in other niche areas such as the targeted monitoring of radiotherapy to cancer patients.

Dosimetry & Imaging's CEO, Dr Jonathon Wright said he was pleased by the level of investment commitment and the prospects for the company over the next 12 months as it looks to enter the global dosimetry market. "Our technical development work with the phosphor has shown several advantages over traditional phosphor technology and we plan to use these advantages to develop the company over multiple market segments in the coming 24 months," he said.

"The current dosimetry market for instance is dominated by a handful of global players many of whom are using out-dated technology which has resulted in long lead times and high costs. We see a significant opportunity to enter this world-market and this investment will progress our efforts in delivering a new technology."

Dosimetry & Imaging's core technology relates to the discovery (made by University of New South Wales' ADFA campus researchers led by Associate Professor Hans Riesen) of a novel radiation storage phosphor which unlike traditional phosphors is photoexcitable making it more sensitive to the detection of radiation. Unlike most phosphors which are 'wiped' when read, the properties of the photoexcitable phosphor discovered by Associate Professor Riesen's group, result in an 'inherent memory' greatly broadening the potential application of the material.

Tim Hirst, CEO of ANU Connect Ventures, said Dosimetry & Imaging was an attractive investment, led by an experienced team with great prospects going forward. "With a solid intellectual property position, a strong technology and interest already shown by global players, I expect Dosimetry & Imaging to have a very exciting future."

---

*ANU Connect Ventures Pty Ltd is the manager of a \$30 million pre-seed fund of the ANU/ MTAAs Superannuation Venture Capital Partnership Fund established with the support of the ACT Government.*

*Australian Capital Ventures Limited is the manager of the Canberra Business Development Fund, a joint venture between the ACT Government and the Hindmarsh Group.*

**For further information contact Tim Hirst, CEO ANU Connect Ventures (m 0420 942 824, [ceo@anuconnectventures.com.au](mailto:ceo@anuconnectventures.com.au))**